Article Impact Level: HIGH Data Quality: STRONG Summary of Cancer Cell, S1535610825002223. https://doi.org/10.1016/j.ccell.2025.05.013 Dr. David Stahl et al.
Points
- Approximately 60% of aggressive B-cell lymphoma patients lack a durable response to CAR-T therapy, which is now linked to a prognostically relevant myeloid-monocytic gene signature.
- The in-depth analysis identified a distinct population of CSF1R+CD14+CD68+ LAMM cells within the tumor, significantly increasing in patients who experience CAR-T treatment failure.
- These LAMM cells actively inhibit CAR-T cell function through a direct interaction mediated by the PGE2-EP2/EP4 axis, providing a specific mechanism for the observed therapeutic resistance.
- In an autochthonous lymphoma mouse model, combining CAR-T cell therapy with a CSF1R inhibitor demonstrated synergistic anti-tumor effects and led to significantly improved overall survival rates.
- The study provides a strong preclinical rationale for investigating the combination of CSF1R blockade with CAR-T cell therapy in future clinical trials for relapsed or refractory B-NHL.
Summary
A study investigating CAR-T cell therapy resistance mechanisms in aggressive B-cell lymphoma (B-NHL) found that approximately 60% of patients with relapsed or refractory (r/r) disease do not achieve a durable response. Through high-dimensional analyses of pre- and post-treatment patient specimens, researchers identified a prognostically relevant lymphoma-associated myeloid-monocytic (LAMM) gene signature that correlates with poor outcomes. This signature corresponds to a distinct cell population within the tumor microenvironment that is notably increased in patients who experience treatment failure.
Further characterization identified this population as CSF1R+CD14+CD68+ LAMM cells. The study determined that these cells are driven by CSF1R-AKT signaling and actively inhibit CAR-T cell function. Cell-cell inference analysis revealed the mechanism of this immunosuppression is a direct interaction with T cells mediated by the PGE2-EP2/EP4 axis. This finding pinpoints a specific pathway through which the tumor microenvironment directly subverts the efficacy of the engineered T-cell immunotherapy.
The researchers utilized an autochthonous lymphoma mouse model to validate these findings therapeutically. In this preclinical setting, the combination of standard anti-CD19 CAR-T cell therapy with a CSF1R inhibitor demonstrated synergistic anti-tumor effects and significantly improved survival. These results provide a strong preclinical rationale for initiating clinical trials that combine CSF1R blockade with CAR-T cell therapy to overcome resistance and improve durable remission rates in patients with r/r aggressive B-NHL.
Link to the article: https://www.sciencedirect.com/science/article/pii/S1535610825002223
References Stahl, D., Gödel, P., Balke-Want, H., Gholamipoorfard, R., Segbers, P., Tetenborg, L., Koker, M., Dörr, J., Gregor, L., Bachurski, D., Rose, F., Simon, A. G., Good, Z., Jakob, J., Häupl, B., Nill, M., Flümann, R., Riet, T., Lange, D., … Ullrich, R. T. (2025). CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma. Cancer Cell, S1535610825002223. https://doi.org/10.1016/j.ccell.2025.05.013
